Skip to content

Investigation of the effects of sweet potato stem/leaf extract - containing soft capsule on cognitive functions in a healthy population: a double-blind, randomized placebo-controlled and parallel study

Investigation of the effects of sweet potato stem/leaf extract - containing soft capsule on cognitive functions in a healthy population: a double-blind, randomized placebo-controlled and parallel study - Investigation of the effects of sweet potato stem/leaf extract - containing soft capsule on cognitive functions

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023401
Enrollment
30
Registered
2018-04-29
Start date
2016-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Intake of Test food (6 weeks) Intake of Test food (6 weeks) Intake of Placebo (6 weeks)

Sponsors

Memory clinic Ochanomizu
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects aged from 50 to 79 years old 2) Diagnosis by the principal investigator: mild cognitive impairment 3) Subjects should have an adequate understanding of the objectives and details of this study and the ability to give written informed consent for participation in the study by themselves

Exclusion criteria

Exclusion criteria: 1) Individuals who take anti-dementia drugs 2) Individuals who take health foods relating cognitive function 3) Individuals judged as dementia for the results of HDS-R by the investigator 4) Individuals judged as depression for the results of GDS-S-J by the investigator 5) Individuals having difficulty in color vision 6) Individuals having difficulty in handling for a injury or operation etc. 7) Individuals who took part in another clinical study (intake of a supplemental food or medicine or composition applied to the skin) within 1 month prior to the start of the present study or who are currently taking part in another clinical study or who are willing to take part in another clinical study. 8) Individuals judged inappropriate for the study by the principal investigator

Design outcomes

Primary

MeasureTime frame
Cognitrax Alzheimer's Disesase Assessment Scale-cognitive component -Japanese version

Secondary

MeasureTime frame
Safety evaluation, Oxidative stress markers in Blood, Brain-derived neurotrophic factor in Blood

Countries

Japan

Contacts

Public ContactHitomi Saito

FUJIFILM Corporation Pharmaceutical & Healthcare Research Laboratories

Hitomi.saito@fujifilm.com080-2119-4836

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026